The new, thorough genetic test that Orchid, a reproductive technology business, announced on Tuesday could ease the minds of many American expectant parents.
In order to help couples undergoing in vitro fertilization—a kind of treatment for those experiencing infertility or who may be at danger of passing on genetic issues—the business is releasing the first full genome sequencing report for embryos that is intended for commercial use.
IVF involves removing a woman’s mature eggs, fertilising them in a lab, and then transferring the viable embryos into the uterus after around two weeks of daily hormone injections.
Orchid claims that their novel test will assist couples in determining whether genetic risks associated with their embryos include chromosomal abnormalities, birth deformities, neurodevelopmental problems, and malignancies that manifest in childhood and adulthood but were previously only detected postnatally.
In an interview with CNBC, Noor Siddiqui, the founder and CEO of Orchid, stated, “This is a big advance in the quantity of information parents can have.” You have complete control and certainty over a process that has historically been completely up to chance. How you choose to use that information is really up to you.
As per the company’s statement, Orchid’s technology is able to sequence over 99% of an embryo’s genome, whereas the current tests usually read only about.25%.
The Institute for Reproductive Health states that infertility is an expensive procedure, with an average cost of over $12,000 in the United States. A successful outcome is not assured, and some patients require several IVF cycles before becoming pregnant.
IVF does not include any new stages or hazards, but couples using Orchid’s genetic test will pay an extra $2,500 for each embryo that is sequenced, according to Siddiqui. According to her, as the company expands its operations and adds more automation, the cost of the report should decrease.
We want to ensure that everyone can use this, stated Siddiqui.
Tuesday marks the launch of Orchid’s technology at IVF clinics in major cities like Los Angeles, Chicago, Miami, and Austin. Siddiqui said that patients can request that Orchid be made available at other clinics.
Source (CNBC)
